VPC
TSHA icon

Vestal Point Capital’s Taysha Gene Therapies TSHA Stock Holding History

Vestal Point Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.5M Buy
18,000,000
+4,250,000
+31% +$19.8M 2.25% 13
2025
Q4 		$75.6M Buy
13,750,000
+8,250,000
+150% +$40.1M 2.57% 11
2025
Q3 		$18M Buy
5,500,000
+2,500,000
+83% +$7.08M 0.81% 44
2025
Q2 		$6.93M Buy
+3,000,000
New +$6.52M 0.36% 49

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vestal Point Capital's TSHA Position: Q1 2026 in Review

Vestal Point Capital increased its Taysha Gene Therapies (TSHA) stake by 31% in Q1 2026, buying an estimated $19.8M and bringing the position to 18,000,000 shares worth $80.5M. The position accounts for 2.25% of the portfolio, ranked #13.

Vestal Point Capital first reported a position in TSHA in Q2 2025 and has held it in 4 quarters since. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Vestal Point Capital held 18,000,000 shares of Taysha Gene Therapies worth $80.5M as of Q1 2026.
  • Vestal Point Capital bought 4,250,000 Taysha Gene Therapies shares in Q1 2026, an estimated $19.8M.
  • Taysha Gene Therapies made up 2.25% of Vestal Point Capital's portfolio in Q1 2026, its #13 holding.
  • Vestal Point Capital first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 4 quarters since.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.